 CHICAGO--BUSINESS WIRE-- GvokeHypoPen--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use RTU injectable and infusible drug formulations, announced that yesterday the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has adopted a positive Opinion for OgluoTM glucagon. Ogluo is the EU trade name for Xeris RTU glucagon for injection. The CHMP recommen 